Diagnostics

Biomarkers to predict response to treatment in metastatic melanoma patients.

A research group from the Biomedical Research Institute of Málaga (IBIMA) has developed a new biomarker panel to predict response to treatment in metastatic melanoma patients.

Oficina de TRANSFERENCIA DE TECNOLOGÍA
Sistema Sanitario Público de Andalucía



Description

Melanoma is a tumor of great molecular complexity with a great variability of mutations that define the type of treatment.

Currently, the study of the presence or absence of mutations in the BRAF oncogene in this type of patients, mainly in those who present metastasis, is being fundamental, since it is present in between 40 and 50% of them.

Treatment with immune checkpoint inhibitors is the most widely used treatment for metastatic melanoma with BRAF mutations, for which specific therapies have been developed. These treatments produce large tumor regression responses and a high increase in the number of survivors and in the life expectancy of these patients, in those who respond. However, it was necessary to develop a strategy to predict or predict the response of these patients.

To this end, our researchers have developed a panel of genetic biomarkers that can predict or predict the response of patients with metastatic melanoma who carry BRAF mutations to treatment with BRAF and MEK inhibitors.

https://www.ibima.eu/grupo_investigacion/bases-moleculares-proliferacion-celular/
ps://www.ibima.eu/grupo_investigacion/investigacion-clinica-y-traslacional-en-cancer/

Intellectual Property

This technology is protected by a national patent application with possibility of international extension.

Advantanges

- This panel of genetic biomarkers provides a methodology for the prediction or prognosis of patient response to current immunotherapy treatment of higher incidence, which may allow **the development of a diagnostic kit or device**.
- Thanks to the prediction of prognosis, p**atients with worse prognosis can be followed more closely**.
- This panel allows a further step towards personalized medicine, enabling **more patient-focused and efficient clinical care**.

Aims

The researcher is looking for partnership and/or license agreement for the development and exploitation of the technology through the development of a diagnostic kit or device.

Classification

Area: Diagnosis
Technology: Genetic biomarkers
Pathology: Cancer

Junta de Andalucía
Consejería de Salud y Familias
FIMABIS
FUNDACIÓN PUBLICA ANDALUZA PARA LA INVESTIGACIÓN DE MÁLAGA EN BIOMEDICINA Y SALUD
ibima
Calle Doctor Miguel Díaz Recio, 28, local, 29010. Málaga. SPAIN
+34 951 440 260 +34 951 440 263 transferencia@ibima.eu
www.ibima.eu